Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Medical Oncology-Hematology Fellowship Program; Co-Director, Center for Thoracic Cancers; Chief, Thoracic Oncology
Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. As a thoracic oncologist she cares for patients with cancers of the chest including lung cancer, mesothelioma and thymoma. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at Yale. She received her medical degree from Mount Sinai School of Medicine and completed a Masters in Public Health degree from the Harvard School of Public Health. She conducts clinical and translational research on lung cancer with a focus on investigating biomarkers and novel treatment strategies in non-small cell lung cancer. Her specific research interests include EGFR mutation positive lung cancer, immunotherapeutics for lung cancer, and...
Associate Professor; Associate Cancer Center Director, Clinical Initiatives
I currently serve as an Associate Professor of Medicine in the Section of Medical Oncology, specializing in thoracic oncology, with a background in translational research in metastasis, as well as extensive experience in clinical practice in both academic and community settings. My clinical focus has been to build a small cell lung cancer program at Yale with a comprehensive portfolio of clinical trials testing novel therapeutics for these patients. My research interests focus on development of clinical trials and translational studies to test novel agents and combinations with immune checkpoint inhibitors for both small cell and non-small cell lung tumors. I have helped to build our SCH Network and oversee operations, quality efforts and clinical research in our Smilow Care Centers. I have a particular focus in quality measurement and improvement and have worked to achieve ASCO QOPI...
Professor of Internal Medicine (Medical Oncology); Chief, Thoracic Medical Oncology
Dr. Gettinger is internationally recognized for his expertise in lung cancer treatment and research. He is best known for his work in immunotherapy and targeted therapy for non-small cell lung cancer. He currently leads several clinical trials evaluating novel therapies for patients with lung cancer. His primary translational research interests include understanding mechanisms of sensitivity and resistance to molecularly targeted therapies and immunotherapies.
Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Medical Oncology-Hematology Fellowship Program; Co-Director, Center for Thoracic Cancers; Chief, Thoracic Oncology
Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. As a thoracic oncologist she cares for patients with cancers of the chest including lung cancer, mesothelioma and thymoma. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at Yale. She received her medical degree from Mount Sinai School of Medicine and completed a Masters in Public Health degree from the Harvard School of Public Health. She conducts clinical and translational research on lung cancer with a focus on investigating biomarkers and novel treatment strategies in non-small cell lung cancer. Her specific research interests include EGFR mutation positive lung cancer, immunotherapeutics for lung cancer, and...
Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Deputy Director, Yale Cancer Center; Chief of Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Assistant Dean for Translational Research, Yale School of Medicine; Program Director, Master of Health Science - Clinical Investigation Track (MHS-CI)
Dr. Herbst is nationally recognized for his leadership and expertise in lung cancer treatment and research. He is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies. Learn more about Dr. Herbst >> Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs. He has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib), which have...
So Yeon Kim, MD, is an Assistant Professor of Medicine (Medical Oncology) at Yale School of Medicine. Dr. Kim completed her undergraduate studies at Princeton University and received her medical degree from Albert Einstein College of Medicine. She completed her internal medicine residency at Tufts Medical Center and completed her hematology oncology fellowship at Montefiore Medical Center. Dr. Kim's clinical practice is focused primarily on caring for patients with thoracic malignancies. In 2022, she received the ASCO Merit Award based on her research on MET exon14 skipping mutations in non-small cell lung cancer. Her ongoing research interests include targeted treatment and immunotherapy approaches in lung cancer.
Associate Professor of Therapeutic Radiology; Vice Chair for Clinical Research, Therapeutic Radiology; Chief, Thoracic Radiotherapy Program, Therapeutic Radiology; Chief, PET-Guided Radiotherapy Program, Therapeutic Radiology; Assistant Medical Director, Clinical Trials Office, Yale Cancer Center; Head of Advisory House, Horstmann House, Office of Student Affairs
Dr. Henry S. Park is a board-certified radiation oncologist who serves as associate professor, vice chair for clinical research, chief of thoracic radiotherapy, and chief of PET-guided radiotherapy for the Department of Therapeutic Radiology at the Yale School of Medicine. For the Yale Cancer Center, he is an assistant medical director of the Clinical Trials Office, where he also leads the radiation oncology committee and is associate leader of the lung clinical research team. For the medical school's Office of Student Affairs, he is the head of one of the six advisory houses (Horstmann House). He has previously held roles as the associate residency program director, medical student electives director, and continuing medical education director for radiation oncology. Dr. Park received his undergraduate degree from Yale College, master's degree from the Harvard School of Public Health, and...
Dr. Wilson graduated from Duke University and received his PhD at Yale University and MD at Harvard Medical School. He completed an internship and residency at Brigham and Women's Hospital and a fellowship in medical oncology at the Dana-Farber Cancer Institute and Massachusetts General Hospital. He completed a research fellowship at Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT. His research focuses on the identification and characterization of genetic vulnerabilities in cancer as well as genetic determinants of sensitivity and resistance to targeted therapies.